Federal Register / Vol. 82, No. 174 / Monday, September 11, 2017 / Notices 42687 

HIV-positive adults. VRC01 is currently 

being evaluated in a phase II clinical 

trial for prevention of HIV–1 

acquisition. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Monoclonal antibodies to treat and/or 

diagnose HIV and/or AIDS 

• Immunoassays and kits 

Competitive Advantages 

• Monoclonal neutralizing antibodies 

prevent viral entry into cells 

• Monoclonal neutralizing antibodies 

can be used for vaccine design and to 

develop diagnostics for HIV–1 

Development Stage 

• In vitro data available 

• In vivo data available (animal) 

• In vivo data available (human) 

• Clinical Phase I 

Inventors: John Mascola, Mark 

Connors, Peter Kwong, Gary Nabel, 

Mario Roederer, Xueling Wu (all from 

NIAID). 

Publications 

Nabel G et al. (2015) Broadly 

Neutralizing Human 

Immunodeficiency Virus Type 1 

Antibody Gene Transfer Protects 

Nonhuman Primates from Mucosal 

Simian-Human Immunodeficiency 

Virus Infection. J Virol. 

89(16):8334–45. [PMID26041300]. 

Nabel G et al. (2014) Enhanced potency 

of a broadly neutralizing HIV–1 

antibody in vitro improves 

protection against lentiviral 

infection in vivo. J Virol. 

88(21):12669–82. [PMID:25142607]. 

Wu X et al. (2010) Immunotypes of a 

quaternary site of HIV–1 

vulnerability and their recognition 

by antibodies. J Virol. 2011: 

85(9):4578–85. [PMID:21325411]. 

Zhou T et al. (2010) Structural basis for 

broad and potent neutralization of 

HIV–1 by antibody VRC01. Science. 

329(5993):811–7. [PMID: 

20616231]. 

Intellectual Property: HHS Reference 

No: E–300–2009 and E–051–2012. The 

E–300–2009 family includes U.S. Patent 

Application. 13/498,286, filed March 

23, 2012 (Issued); Australia Patent 

Application 2010298025, filed 

September 24, 2010 (Issued); China 

Patent Application 201080053616.5 

filed September 24, 2010 (Issued); E.U. 

Patent Application 10760878.8 filed 

September 24, 2010 (Pending); India 

Patent Application 588/KOLNP/2012 

filed March 13, 2012 (Pending); South 

Africa Patent Application 212/02116 

filed September 24, 2017 (Pending); 

Canada Patent Application. 2274636 

filed September 24, 2017 (Pending). 

The E–051–2012 family includes U.S. 

Patent Application 14–363,740, filed 

June 6, 2014 (Issued); Australia Patent 

Application. 2012347453, filed 

December 10,2010 (Issued); China 

Patent Application 201280069415.3, 

filed December 10, 2012 (Pending); E.U. 

Patent Application 1285597.6, filed 

December 10, 2012 (Pending); Indian 

Patent Application 4661/DELNP/2014, 

filed December 10, 2012 (Pending); 

South Africa Patent Application 2014/ 

04077, filed December 10, 2012 

(Pending). 

Licensing Contact: Dr. Vince 

Contreras, 240–669–2823; 

Vince.Contreras@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize Monoclonal antibodies 

to treat and/or diagnose HIV and/or 

AIDS. 

For collaboration opportunities, 

please contact Dr. Vince Contreras, 240– 

669–2823; Vince.Contreras@nih.gov. 

Dated: September 1, 2017. 

Suzanne Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2017–19088 Filed 9–8–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health and Human 

Development; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development Initial 

Review Group Reproduction, Andrology, and 

Gynecology Subcommittee. 

Date: October 20, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Dennis E. Leszczynski, 

Ph.D., Scientific Review Administrator 

Division of Scientific Review National 

Institute of Child Health and Human 

Development, NIH, 6710B Bethesda Drive, 

Bethesda, MD 20892, (301) 435–2717, 

leszczyd@mail.nih.gov. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; Point of Care 

Technologies for the Evaluation and 

Management of Obstetrics, Neonatal, and 

Pediatric Critical Care Patients, and for 

Patients With Disorders of Reproductive 

Tract and Infertility. 

Date: November 6, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Sathasiva B. Kandasamy, 

Ph.D., Scientific Review Administrator 

Division of Scientific Review National 

Institute of Child Health and Human 

Development, 6710B Bethesda Drive, 

Bethesda, MD 20892, (301) 435–6680, 

skandasa@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: September 5, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–19089 Filed 9–8–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 


asabaliauskas on DSKBBXCHB2PROD with NOTICES